SETH ORLOW, M.D.
Dermatology in New York, NY
License number
New York 180071
Category
Osteopathic Medicine
Type
Dermatology
Address
Address
550 R, New York, NY 10016
Phone
(212) 263-8243
Personal information
See more information about SETH ORLOW at radaris.comName
Address
Phone
9 E 96Th St #11A, New York, NY 10128
9 E 96Th St, New York, NY 10128
460 Park, New York, NY 10022
5301 Avenue At East 30, New York, NY 10001
530 1 St, New York, NY 10016
Organization information
See more information about SETH ORLOW at bizstanding.comSeth Orlow MD,PHD
530 1 Ave, New York, NY 10016
Industry:
Dermatologist, Pediatric Dermatologist, Pediatrician
Phone:
(212) 263-5889 (Phone)
Seth Jay Orlow
Professional information
Dr. Seth Orlow, New York NY - MD (Doctor of Medicine)
Specialties:
Pediatric Dermatology
Address:
NY Mohs Laser Dermatology
530 1St Ave SUITE 7R, New York 10016
(212) 263-5889 (Phone)
550 1St Ave, New York 10016
(212) 263-8243 (Phone)
530 1St Ave SUITE 7R, New York 10016
(212) 263-5889 (Phone)
550 1St Ave, New York 10016
(212) 263-8243 (Phone)
Certifications:
Dermatology, 1990, Pediatric Dermatology, 2004
Awards:
Healthgrades Honor Roll
Languages:
English, Spanish
Hospitals:
NY Mohs Laser Dermatology
530 1St Ave SUITE 7R, New York 10016
550 1St Ave, New York 10016
NYU Langone Medical Center
550 1St Ave, New York 10016
530 1St Ave SUITE 7R, New York 10016
550 1St Ave, New York 10016
NYU Langone Medical Center
550 1St Ave, New York 10016
Education:
Medical School
Albert Einstein College Of Medicine Of Yeshiva University
Graduated: 1986
Mt Sinai Med Center
Graduated: 1987
Yale New Haven Hospital
Graduated: 1990
Yale University Med Center
Albert Einstein College Of Medicine Of Yeshiva University
Graduated: 1986
Mt Sinai Med Center
Graduated: 1987
Yale New Haven Hospital
Graduated: 1990
Yale University Med Center
Seth Orlow, New York NY
Specialties:
Dermatologist, Pediatric Dermatologist, Pediatrician
Address:
530 First Ave #7R, New York, NY 10016
Education:
Medical School - Albert Einstein College of Medicine Graduated 1986
Mt Sinai School of Medicine, NY Graduated 1987 (Internship)
Yale Medical School,New Haven,CT Graduated 1989 (Residency)
Yale Medical School,New Haven,CT Graduated 1990 (Fellowship)
Mt Sinai School of Medicine, NY Graduated 1987 (Internship)
Yale Medical School,New Haven,CT Graduated 1989 (Residency)
Yale Medical School,New Haven,CT Graduated 1990 (Fellowship)
Languages:
English
Professional Memberships:
American Academy of Dermatology, Society for Pediatric Dermatology, Society for Investigative Dermatology
Awards and Publications:
see: http://www.med.nyu.edu/people/orlows01.html
Board certifications:
American Board of Dermatology, Pediatric Dermatology (Dermatology)
Hospital affiliations:
Lenox Hill Hospital
About:
My practice is focused on the evaluation and management of disorders of the skin, hair and nails in infants, children and teenagers.
Inhibition Of Pigmentation By Inhibition Of Fatty Acid Synthase
US Patent:
6749840, Jun 15, 2004
Filed:
May 2, 2002
Appl. No.:
10/137632
Inventors:
Seth J. Orlow - New York NY
Andrea Hall - Astoria NY
Andrea Hall - Astoria NY
Assignee:
New York University - New York NY
International Classification:
A61K 7135
US Classification:
424 62, 424400, 424401, 514410
Abstract:
The invention provides novel methods and pharmaceutical compositions designed to decrease melanin production by inhibiting fatty acid synthase in a melanocyte, thereby lightening skin pigmentation.
Indole Alkaloid Compounds As Melanogenesis Promoters And Uses Thereof
US Patent:
2013030, Nov 14, 2013
Filed:
Nov 16, 2011
Appl. No.:
13/885685
Inventors:
Seth J. Orlow - New York NY, US
Li Ni Komatsu - Clarksville MD, US
Li Ni Komatsu - Clarksville MD, US
Assignee:
NEW YORK UNIVERSITY - New York NY
International Classification:
A61K 31/475, A61K 45/06, A61K 31/4375
US Classification:
424 59, 514280, 51426334
Abstract:
Provided are indole alkaloid compounds of formula I, for example, pubescine, and the use of such compounds and compositions thereof to promote (e.g., enhance) melanogenesis and pigmentation.Also provided are plant extracts containing a compound of formula I, for example, pubescine, and the use of such a plant extract to promote (e.g., enhance) melanogenesis and pigmentation. The compound or plant extract may be prepared as pharmaceutical and cosmetic compositions, and may be used for the prevention and treatment of conditions that are related to aberrant melanogenesis activity.
Compounds Stimulating And Inhibiting Melanin Formation, And Methods For Screening These Compounds
US Patent:
2004026, Dec 30, 2004
Filed:
Apr 12, 2004
Appl. No.:
10/821981
Inventors:
Seth Orlow - New York NY, US
Young-Tae Chang - New York NY, US
Young-Tae Chang - New York NY, US
Assignee:
New York University - New York NY
International Classification:
C12Q001/00, A61K007/135
US Classification:
424/062000, 435/004000
Abstract:
Trisubstituted triazine compounds are screened for pigment stimulating ability or pigment inhibiting ability. Compounds which bind ATPase increase melanin in the skin or hair. Compounds found to be active are used for screening for other active compounds. Active compounds are used for increasing melanin in the skin or hair, or for decreasing melanin in the skin or hair.
Combination Therapy For The Treatment Of Immunoinflammatory Disorders
US Patent:
2007011, May 17, 2007
Filed:
Jun 16, 2006
Appl. No.:
11/454202
Inventors:
Benjamin Auspitz - Cambridge MA, US
Bradley Brasher - Natick MA, US
Todd Chappell - Boston MA, US
Michael Frank - Boston MA, US
Daniel Grau - Arlington MA, US
Seth Lederman - New York NY, US
Palaniyandi Manivasakam - West Roxbury MA, US
Seth Orlow - New York NY, US
Noah Sachs - South Boston MA, US
Brendan Smith - Somerville MA, US
Bradley Brasher - Natick MA, US
Todd Chappell - Boston MA, US
Michael Frank - Boston MA, US
Daniel Grau - Arlington MA, US
Seth Lederman - New York NY, US
Palaniyandi Manivasakam - West Roxbury MA, US
Seth Orlow - New York NY, US
Noah Sachs - South Boston MA, US
Brendan Smith - Somerville MA, US
International Classification:
A61K 8/49, A61K 38/13, A61K 31/4745, A61K 31/385, A61K 31/522, A61K 31/4178
US Classification:
424059000, 514011000, 514183000, 514263320, 514291000, 514397000, 514471000, 424641000
Abstract:
The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering a non-steroidal immunophilin-dependent immunosuppressant (NsIDI) and a Group A enhancer (e.g., antifungal agent, antigout agent, anti-infective agent, antiprotozoal agent, antiviral agent, humectant, sunscreen, vitamin D compound, microtubuline inhibitor, or zinc salt) or analog or metabolite thereof to the patient. The invention also features a pharmaceutical composition containing an NsIDI and Group A enhancer or analog or metabolite thereof for the treatment or prevention of an immunoinflammatory disorder.
Methods And Compositions For The Treatment Of Cancers, Such As Melanomas And Gliomas
US Patent:
2009027, Oct 29, 2009
Filed:
Apr 8, 2009
Appl. No.:
12/384777
Inventors:
Seth J. Orlow - New York NY, US
Ming Chen - Wayne NJ, US
Ming Chen - Wayne NJ, US
International Classification:
A61K 31/53, A61K 31/4188, A61K 31/505, A61K 31/517, A61K 31/4985, A61K 31/4965, A61P 35/00
US Classification:
514245, 514393, 514275, 5142664, 514249, 51425506
Abstract:
A method of potentiating the efficacy of an antineoplastic agent such as temozolomide, comprises the administration of an antifolate agent as defined herein. Also disclosed are compositions, including pharmaceutical compositions, comprising the antineoplastic agent and an antifolate agent, and the use of such compounds and compositions thereof to treat a variety of cancers, such as melanoma. Unit dosage forms and kits are also contemplated and disclosed.
Quinoline Compounds As Melanogenesis Modifiers And Uses Thereof
US Patent:
2009029, Dec 3, 2009
Filed:
Apr 30, 2009
Appl. No.:
12/433863
Inventors:
Seth J. Orlow - New York NY, US
Li Ni Komatsu - Silver Spring MD, US
Li Ni Komatsu - Silver Spring MD, US
International Classification:
A61K 31/4709, A61K 31/47
US Classification:
514305, 514311, 514313, 514314
Abstract:
A method of identification of quinoline compounds (formula I) that modify melanin synthesis (melanogenesis), and the use of such compounds and compositions thereof to control (e.g., inhibit) melanin production are disclosed.The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of conditions that are causally related to aberrant melanogenesis activity including by way of non-limiting example, pigmentation deficiencies (albinism) and hyperpigmentation and others.
Tricyclic Compounds As Melanogenesis Modifiers And Uses Thereof
US Patent:
2009030, Dec 10, 2009
Filed:
Apr 30, 2009
Appl. No.:
12/433860
Inventors:
Seth J. ORLOW - New York NY, US
Li Ni KOMATSU - Silver Spring MD, US
Li Ni KOMATSU - Silver Spring MD, US
International Classification:
A61K 31/135, A61K 31/55, A61K 31/335, A61P 17/00
US Classification:
424 62, 514654, 514217, 514450
Abstract:
A method of identification of tricyclic compounds (formula I) that control melanin synthesis (melanogenesis), and the use of such compounds and compositions thereof to modify (e.g., inhibit) melanin production are disclosed.The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of conditions that are causally related to aberrant melanogenesis activity including by way of non-limiting example, hyperpigmentation and others.
Assay For Melanogenesis
US Patent:
7378232, May 27, 2008
Filed:
May 9, 2003
Appl. No.:
10/435439
Inventors:
Seth J. Orlow - New York NY, US
Prashiela Manga - Cincinnati OH, US
Liliana Staleva - New York NY, US
Prashiela Manga - Cincinnati OH, US
Liliana Staleva - New York NY, US
Assignee:
New York University - New York NY
International Classification:
C12Q 1/00, C12Q 1/02
US Classification:
435 4, 435 29
Abstract:
The invention provides methods for the identification of agents that modify or mimic P protein function. Cells expressing a P protein are generally more sensitive to toxins, and changes in cell viability and/or cell death after exposure of P protein-expressing cells to an agent and a toxin is an indication that such an agent is a modifier of P protein expression. The invention also provides methods for the treatment of melanoma and other cancers.